Related Experiment Video
Updated: Dec 21, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
Combination of sirtuin 3 and hyperoxia diminishes tumorigenic properties of MDA-MB-231 cells
Iva I Podgorski1, Marija Pinterić1, Dora Marčinko1
1Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
Aims:
Since the role of the major mitochondrial NAD+-dependent deacetylase, sirtuin 3 (Sirt3), is differential in cancer, opposite to the well-known tumor-suppressing effect of hyperoxia, this study aimed to investigate the role of Sirt3 in triple-negative breast cancer (TNBC) cell line MDA-MB-231 upon hyperoxic (95% O2) conditions.
Main Methods:
MDA-MB-231 cells were stably transfected with Flag-tagged Sirt-3 or empty plasmid. Western blot and real-time PCR were used to monitor the expression of proteins or genes involved in mitochondrial biogenesis, metabolic regulation and antioxidant defense. Immunocytochemistry and confocal microscopy were used to confirm the cellular localization and abundance of proteins. Flow cytometry was used to analyze mitochondrial mass, potential and ROS production, and MTT test as a measure of metabolic activity. Mitotic index analysis, colony-forming unit assay, DNA damage and Annexin V-FITC analyses were used to assess the differences in the growth and apoptosis rate.
Key Findings:
Although Sirt3 seemed to improve mitochondrial properties by increasing mitochondrial mass and potential, metabolic activity (Warburg effect) and antioxidative defense (SOD2, Cat), it also increased mitochondrial ROS, induced DNA damage, timp-1 expression, formation of multinucleated cells and apoptosis, and finally markedly reduced the proliferation of MDA-MB-231 cells. All these effects were even more evident upon the hyperoxic treatment, thus pointing towards combined negative effect of Sirt3 and hyperoxia on MDA-MB-231 cells.
Significance:
Both Sirt3 and hyperoxia, alone or in combination, have the potential to negatively affect the malignant properties of the MDA-MB-231 cells and should be further explored as a possible therapy for TNBC.
Insights
Sirtuin 3 (Sirt3) and hyperoxia negatively impact triple-negative breast cancer (TNBC) cells. This combined effect, along with individual impacts, suggests potential therapeutic strategies for TNBC.
Area of Science:
- Mitochondrial biology
- Cancer research
- Cellular metabolism
Background:
- Sirtuin 3 (Sirt3) plays a complex role in cancer.
- Hyperoxia, or high oxygen levels, typically suppresses tumors.
- The interaction between Sirt3 and hyperoxia in triple-negative breast cancer (TNBC) is not well understood.
Purpose of the Study:
- To investigate the role of Sirt3 in MDA-MB-231 TNBC cells under hyperoxic conditions.
- To determine the combined effects of Sirt3 and hyperoxia on TNBC cell behavior.
Main Methods:
- Stable transfection of MDA-MB-231 cells with Sirt3 or empty plasmid.
- Analysis of mitochondrial biogenesis, metabolic regulation, and antioxidant defense markers via Western blot and qPCR.
- Assessment of mitochondrial function, reactive oxygen species (ROS) production, metabolic activity, proliferation, DNA damage, and apoptosis using flow cytometry, MTT assays, and other cellular assays.
Main Results:
- Sirt3 enhanced mitochondrial properties but also increased ROS, DNA damage, and apoptosis, ultimately reducing proliferation.
- Hyperoxia exacerbated these effects, indicating a combined negative impact on TNBC cells.
- The Warburg effect and antioxidant defenses (SOD2, Cat) were modulated by Sirt3.
Conclusions:
- Both Sirt3 and hyperoxia, individually and combined, demonstrate potential to inhibit malignant properties of MDA-MB-231 cells.
- These findings suggest Sirt3 and hyperoxia as potential therapeutic avenues for TNBC.
- Further research is warranted to explore their clinical applicability in TNBC treatment.
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
